Top Tweets for #multiTAA
📢 Today we reported our third quarter 2024 financial results and provided business updates.
Follow the link for more information: https://t.co/dq0ITlmmy8
#multiTAA #immunotherapy #ClinicalTrials #CellTherapy #patients #cancer #biotech #lymphoma #AML #PancreaticCancer
📢Exciting News!
✨ Our first patient with #lymphoma treated with MT-601 remains in complete response 6 months after MT-601 treatment! ✨
Read the full story here: https://t.co/vib4rnI6OV
#immunotherapy #CART #multiTAA #ClinicalTrials #CellTherapy #patients #cancer #biotech
Today we reported nonclinical data from our #multiTAA-specific T cell product candidate MT-401 in #AML cells after hypomethylating agent administration.
We also announced that the Company was awarded a $2 million grant from NIH.
More info: https://t.co/4CiKKLRLfA
#celltherapy
Trial of T-cell therapy for lung cancer begins at UCLH
▪️Researchers say the clonal neoantigen #T_cell (cNeT) therapy has the potential to transform the treatment of cancer
▪️Not so different from $MRKR ‘s
#multiTAA or #MT_401 or #Zelenolwucel
https://t.co/9UulV3NCCV
Genocea Announces Material Transfer and #License_Option Agreement w/ Shionogi for Proprietary GEN-003 HSV-2 Antigens
Congrats $GNCA longs!
▪️The field of #NeoAg_based Cell_Therapy is opening up! Next move will be by $MRKR on multiple fronts #MultiTAA https://t.co/gl64Hcvh7H
Another Step Towards Earlier Detection of #PancCancer
▪️Another Step Towards Earlier Detection of #PancCancer
— Risk-prediction model uses #biomarkers added to clinical & genetic risk factors
#BCMHouston $MRKR #MultiTAA: among most promising therapy
https://t.co/k81xONXXT2
Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer
It seems that cell therapy based on neoAg spread,ie, $MRKR ‘s #MultiTAA cud b an attractive way2 deal w/ tumor heterogeneity https://t.co/QwuFE0J2bz
Role of oncogenic #KRAS in the #diagnosis, #prognosis and #treatment of #pancreatic_cancer | Nature Reviews Gastroenterology & Hepatology |
@BCM $MRKR developing Cell_Therapy #multiTAA for tx of #PDAC
https://t.co/hwxfcIs6TP
#Colorectal and #pancreatic cancer on the rise worldwide - up 10% for both
$MRKR / @BCM ‘s upcoming #MultiTAA cell therapy could bring significant clinical benefits to patients with #PancCancer
https://t.co/903gqXKC6M
Thoughts on 2019 FDA most impactful approvals:
2) Olaparib approved for first-line maintenance therapy in patients with metastatic #PancCan even w/o OS benefits (PFS only). Upcoming #multiTAA #cell_therapy could be a better option. More data in 2020 2️⃣
$AZN $MRKR @bcmhouston
A high-profile review on the yearly progress of #PancreaticCancer gave PROMINENT mention to the ”non-engineered autologous cell therapy” reported by Dr. Brandon Smaglo of @BCMhouston and $MRKR in July. #multiTAA
“Year in Review: Pancreatic Cancer”
https://t.co/4FB3ZGnfam
$MRKR #MultiTAA could potentially fill the void left by failure of $GSK drug. It’s safe, efficacious (in early rounds), & inexpensive; as it’s non-engineered, personalized to provide adaptive T cells (T4/T8)
An early failure in #PancreaticCancer - RIP1 kinase inhibitor as a modulator of the immune suppressive microenvironment.
Very promising preclinical data in @Cancer_Cell last year:
https://t.co/dsEdO1vrzx
But the toxicities were overwhelming. Back to the drawing board.
$GSK ‘s #RIPK1 inhibitor dead on arrival
A brief line from its Q3 financials posted this morning read: “GSK095 for #PancCancer was terminated as part of ongoing portfolio prioritisation”
$MRKR #MultiTAA
▪️Safe, efficacious in early clinical findings https://t.co/pMQJSZvMjR
Imaging tumor stiffness could help enhance treatment for #breastcancer and #PancreaticCancer
$MRKR #multiTAA
$AZN #Lynparza #PARPi https://t.co/vypvDM7fwm
A new, fascinating article just published in Nature (10/2/2019)
“Fungi accelerate pancreatic cancer”
$MRKR #multiTAA #Cell_Therapy for
#PanCancer https://t.co/DYy3nTEecW
“Why Can’t We Stop Pancreatic Cancer?” - The New York Times
A timely and well written article, highly relevant to Marker’s transformative T cell therapy.
$MRKR
#multiTAA
#pancCancer https://t.co/diZIyTBdyK
$MRKR Arm B: 2nd line treatment with #MultiTAA in patients with pancreatic cancer who could not tolerate DoC chemotherapy:
#PancCancer @BCMhouston
$MRKR September slides update:
Marker for the first time (I believe) offered a high-lighted version, IN RED, of its pancreatic trial results. This is very informative & lucid for those who are interested but haven’t had time to explore.
Arm A: FL #multiTAA w/ SoC chemotherapy:
Last Seen Hashtags on Sotwe
ZeroTwoDarilingInTheFranxx
Seen from United States
korean camgirl
vintage ass
Seen from Mexico
ديوت_بدوي
Seen from Saudi Arabia
cuck
Seen from Egypt
Teenage
gazianteptravestileri
Seen from Turkey
แนวครอบครัว
Seen from Thailand
ixlii()*
Seen from Australia
nietallemoslimszijnmediawaardig
Seen from Korea
Most Popular Users
Elon Musk 
@elonmusk
240.9M followers
Barack Obama
@barackobama
119.2M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Cristiano Ronaldo
@cristiano
111.4M followers
Narendra Modi
@narendramodi
107M followers
Rihanna
@rihanna
97.9M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91.1M followers
KATY PERRY
@katyperry
88.1M followers
Taylor Swift
@taylorswift13
82M followers
Lady Gaga
@ladygaga
73.5M followers
Virat Kohli
@imvkohli
70.6M followers
Kim Kardashian
@kimkardashian
70M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
64.1M followers
Neymar Jr
@neymarjr
63.4M followers
The Ellen Show
@theellenshow
62.4M followers
CNN
@cnn
61.9M followers
Selena Gomez
@selenagomez
61.2M followers
X
@x
60.8M followers